Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CYTX Cytori Therapeutics (CYTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Cytori Therapeutics Stock (NASDAQ:CYTX) 30 days 90 days 365 days Advanced Chart Get Cytori Therapeutics alerts:Sign Up Key Stats Today's Range$1.22▼$1.2850-Day Range$0.20▼$0.2152-Week Range$0.20▼$0.75Volume16,094 shsAverage Volume915,302 shsMarket Capitalization$27.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.Read More… Receive CYTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTX Stock News HeadlinesCytori Cell Research Institute Inc.August 10, 2024 | wsj.comCheckpoint Therapeutics Inc (CKPT)February 9, 2024 | investing.comElon has entered the MarkBeat conversationSpivey's firm accurately warned of both the 2008 and 2020 stock market crashes and have charged institutional clients as much as $100,000 for a single report. But on this new, viral broadcast, Rob shares his firm's latest - and perhaps most important - prediction with MarketBeat readers, 100% free of charge. You know, it's stock market stories just like this one that inspired me to start MarketBeat in the first place. It's been my mission to get big, timely, under-the-radar stories in front of you... and help you connect the dots before the gains have been made by Wall Street.February 10, 2025 | Altimetry (Ad)Sage Therapeutics Inc SAGENovember 4, 2023 | morningstar.com5 Biotech Stocks Under $10 Blasting HigherSeptember 27, 2023 | thestreet.comWomen’s Health Therapeutics Market Research Report by Type, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19October 16, 2022 | finance.yahoo.com8 Stocks Under $10 Ripping HigherAugust 29, 2022 | thestreet.comSee More Headlines CYTX Stock Analysis - Frequently Asked Questions How were Cytori Therapeutics' earnings last quarter? Cytori Therapeutics Inc (NASDAQ:CYTX) issued its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company earned $0.70 million during the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative trailing twelve-month return on equity of 272.70%. When did Cytori Therapeutics' stock split? Cytori Therapeutics shares reverse split before market open on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Cytori Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), BCE (BCE), Celldex Therapeutics (CLDX) and Micron Technology (MU). Company Calendar Last Earnings5/14/2019Today2/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryBiotechnology Current SymbolNASDAQ:CYTX CUSIP23283K10 CIK1095981 Webwww.cytori.com Phone858-458-0900FaxN/AEmployees37Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,630,000.00 Net Margins-242.60% Pretax MarginN/A Return on Equity-272.70% Return on Assets-56.23% Debt Debt-to-Equity Ratio0.39 Current Ratio0.46 Quick Ratio0.30 Sales & Book Value Annual Sales$3.67 million Price / Sales7.47 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book3.53Miscellaneous Outstanding Shares22,160,000Free FloatN/AMarket Cap$27.40 million OptionableNot Optionable Beta1.96 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:CYTX) was last updated on 2/10/2025 by MarketBeat.com Staff From Our PartnersA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTop 5 Trump Stocks for His First 100 DaysRight now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredElon’s ‘Agents’ StrikeHe might be the richest man on the planet – but Elon Musk just landed himself a new job... In a move that c...Altimetry | Sponsored2,000% Jump in MillionairesDuring Calvin Coolidge's presidency, America saw the number of millionaires surge by over 2,000%. Now, with...The Oxford Club | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytori Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.